Evidence map›Paper›PMID 23666469›Full record

ReviewCurrent rheumatology reports2013

Update on oxalate crystal disease.

Elizabeth C Lorenz, Clement J Michet, Dawn S Milliner, John C Lieske

Open access · greenAbstract readReview
In one paragraph

Review in Current rheumatology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 96 citations in OpenAlex.

  1. Trial
  2. Trial
  3. [Oxalate-rare crystal disease in joints and kidneys].Zeitschrift fur Rheumatologie · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021
    Article
  17. Review
  18. Genetics of kidney stone disease.Nature reviews. Urology · 2020
    Review
  19. Article
  20. Bar Code Reader - an algorithmic approach to cutaneous occluding vasculopathies? part II medium vessel vasculopathies.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Elizabeth C LorenzDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Clement J Michet
Dawn S Milliner
John C Lieske
Mayo Clinic · USMayo Clinic in Arizona · US

Funding

Primary HyperoxaluriaU54DK083908 · NIDDK · MAYO CLINIC ROCHESTER · PI MILLINER, DAWN SCHMAUTZ · 2009 to 2018
$12.3M
Mayo Clinic Urology O'Brien Research CenterP50DK083007 · NIDDK · MAYO CLINIC ROCHESTER · PI LIESKE, JOHN C · 2008 to 2012
$5.3M
NIDDK NIH HHS P50 DK083007NIDDK NIH HHS U54 DK083908PHS HHS U54KD083908
6 · The paper itself

Abstract

Oxalate arthropathy is a rare cause of arthritis characterized by deposition of calcium oxalate crystals within synovial fluid. This condition typically occurs in patients with underlying primary or secondary hyperoxaluria. Primary hyperoxaluria constitutes a group of genetic disorders resulting in endogenous overproduction of oxalate, whereas secondary hyperoxaluria results from gastrointestinal disorders associated with fat malabsorption and increased absorption of dietary oxalate. In both conditions, oxalate crystals can deposit in the kidney leading to renal failure. Since oxalate is primarily renally eliminated, it accumulates throughout the body in renal failure, a state termed oxalosis. Affected organs can include bones, joints, heart, eyes, and skin. Since patients can present with renal failure and oxalosis before the underlying diagnosis of hyperoxaluria has been made, it is important to consider hyperoxaluria in patients who present with unexplained soft tissue crystal deposition. The best treatment of oxalosis is prevention. If patients present with advanced disease, treatment of oxalate arthritis consists of symptom management and control of the underlying disease process.

Indexed as

ArthritisCalcium OxalateHumansHyperoxaluriaSynovial FluidCalcium Oxalate

Identifiers

PMID23666469
PMCPMC3710657
OpenAlexW2076866971

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.